A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer
Phase of Trial: Phase II
Latest Information Update: 22 May 2017
At a glance
- Drugs Capmatinib (Primary)
- Indications Renal cell carcinoma
- Focus Proof of concept; Therapeutic Use
- 24 Aug 2016 Planned End Date changed from 1 Dec 2017 to 1 Jan 2019.
- 24 Aug 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Jan 2018.
- 02 Oct 2015 Treatment table revised with change in dose of INC280 form 600mg to 400 mg . Also, film coated tablets to be used instead of hard gelatin capsules.